Nuveen, LLC Argenx Se Call Options Transaction History
Nuveen, LLC
- $363 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARGX
# of Institutions
507Shares Held
26.2MCall Options Held
561KPut Options Held
286K-
Price T Rowe Associates Inc Baltimore, MD3.64MShares$3.31 Billion0.29% of portfolio
-
Janus Henderson Group PLC London, X02.58MShares$2.34 Billion0.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.19MShares$1.99 Billion2.46% of portfolio
-
Capital World Investors Los Angeles, CA1.96MShares$1.78 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$918 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $50.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...